Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamadermatol.2013.2385 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acral Lentiginous Melanoma. Part II. Staging, Surgical Management, The Role of Systemic Therapy, Shortcomings and Future Directions.
J Am Acad Dermatol
January 2025
Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA; Division of Oncology, Keck School of Medicine, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA. Electronic address:
This comprehensive review navigates the clinical management and challenges of acral lentiginous melanoma (ALM), including staging, surgical interventions, and systemic therapies. Multimodality treatment and clinical trials are recommended for advanced cases.
View Article and Find Full Text PDFThe effect of meloxicam at the time of treatment of hoof-horn lameness in pasture-grazing dairy cattle on time to lameness soundness, pregnancy risk and time to conception; a randomized control trial.
J Dairy Sci
January 2025
Boehringer-Ingelheim Animal Health, Level 2, 3 Te Kehu Way, Mount Wellington, Auckland, New Zealand.
The aims of this study were to assess the effect of meloxicam at the time of lameness treatment for hoof-horn (HH) lesions in dairy cattle on 1) time to lameness soundness post trimming and block application and 2) reproductive success Five seasonal-calving pasture-based dairy farms located in the Waikato region of New Zealand were enrolled into a randomized clinical interventional trial. Farmers were tasked with identifying lame animals over a period of approximately -4 to 6 weeks relative to the herd start of mating (HSM), with lameness subsequently confirmed with lameness score (LS) by trained technicians (0-3 scale, where ≥2 are considered lame). Animals with a LS ≥2 were examined by a veterinarian who then enrolled animals if they presented lame with HH (white-line or sole) lesions.
View Article and Find Full Text PDFThe Dutch Early-Stage Melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I/II cutaneous melanoma.
Eur J Epidemiol
January 2025
Department of Dermatology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Early-stage cutaneous melanoma patients generally have a favorable prognosis, yet a significant proportion of metastatic melanoma cases arise from this group, highlighting the need for improved risk stratification using novel prognostic biomarkers. The Dutch Early-Stage Melanoma (D-ESMEL) study introduces a robust, population-based methodology to develop an absolute risk prediction model for stage I/II melanoma, incorporating clinical, imaging, and multi-omics data to identify patients at increased risk for distant metastases. Utilizing the Netherlands Cancer Registry and Dutch Nationwide Pathology Databank, we collected primary tumor samples from early-stage melanoma patients, with and without distant metastases during follow-up.
View Article and Find Full Text PDFSelf-assessed improved sun protection after diagnosis of melanoma is associated with improved survival.
Clin Exp Dermatol
December 2024
Department of Dermatology, Medical University of Vienna, Vienna, Austria.
Background: Although ultraviolet radiation is the most important risk factor for skin cancer in general, its role in disease control after the diagnosis of melanoma remains to be elucidated.
Objectives: To analyse the association between survival and self-assessed sun protection behaviour after a melanoma diagnosis.
Methods: This was a questionnaire-based pilot study.
Current and emerging treatment options for BRAFV600-mutant melanoma.
Expert Rev Anticancer Ther
January 2025
Royal Marsden Hospital, London.
Introduction: BRAF mutations are the most common driver mutation in cutaneous melanoma, present in 40% of cases. Rationally-designed BRAF targeted therapy (TT) has been developed in response to this, and alongside immune checkpoint inhibitors (ICI), forms the backbone of systemic therapy options for BRAF-mutant melanoma. Various therapeutic approaches have been studied in the neoadjuvant, adjuvant and advanced settings, and there is a wealth of information to guide clinicians managing these patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!